The statements below are read from ASSTON PHARMACEUTICALS LIMITED’s filed results, 2 filed quarters and 5 fiscal years on record, standalone basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: H2 FY25-26 · filed May 30, 2026 · audited
This company files half-yearly statements with the exchange — each column is a six-month period; discrete quarterly figures are not published.
| ₹ Cr | H1 FY26Sep 2025 | H2 FY26Mar 2026Latest | YoYlatest |
|---|---|---|---|
| Sales | 15.4 | 10.1 | — |
| 13.2 | 12.9 | — | |
| Operating profit | 2.23 | -2.80 | — |
| OPM % | 14.5% | -27.8% | — |
| Other income | 1.49 | 4.63 | — |
| Interest | 0.28 | 0.36 | — |
| Depreciation | 0.07 | 0.25 | — |
| Profit before tax | 0.03 | 1.22 | — |
| Tax % | -36.0% | 60.4% | — |
| Net profit | 0.03 | 0.48 | — |
| EPS (₹) | 0.05 | 1.14 | — |
No results filing with a recorded time yet — reactions appear from the first quarter whose announcement we timestamped (May 2026 onward), on the session the market could trade it.
